AnaptysBio CEO Hamza Suria resigns; Daniel Faga named Interim President and CEO

ANAPTYSBIO, INC

Hamza Suria resigned as President, CEO and Class II director effective March 20, 2022.
Suria receives $603,580 salary continuation for 12 months and COBRA reimbursement; consulting through March 2023.
Daniel Faga, former Mirati COO and Spark CBO, appointed Interim CEO effective March 21, 2022.
Faga receives base salary $603,580, 55% target bonus, and 887,043 RSUs vesting over 24 months.
Faga's RSU vests fully on change of control termination or if new CEO hired; severance includes 12 months salary.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Daniel Faga

Interim President and Chief Executive Officer

ANAB · ANAPTYSBIO, INC

Effective: 2022-03-21
Filed: March 21, 2022, 7:59 PM ET

the Company appointed Daniel Faga, a Class I director of the Board, to serve as Interim President and Chief Executive Officer of the Company, effective as of March 21, 2022.

Departed

Hamza Suria

President and Chief Executive Officer

ANAB · ANAPTYSBIO, INC

Effective: 2022-03-20
Successor: Daniel Faga
Filed: March 21, 2022, 7:59 PM ET

On March 20, 2022, Hamza Suria, provided notice to the board of directors (the “Board”) of AnaptysBio, Inc. (the “Company”) of his resignation as President and Chief Executive Officer and as a Class II director of the Company, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Daniel Faga was appointed as Interim President and Chief Executive Officer at ANAPTYSBIO, INC.

Action: appointed
Role: Interim President and Chief Executive Officer

Exact text from the filing

the Company appointed Daniel Faga, a Class I director of the Board, to serve as Interim President and Chief Executive Officer of the Company, effective as of March 21, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Hamza Suria resigned as President and Chief Executive Officer at ANAPTYSBIO, INC.

Action: resigned
Role: President and Chief Executive Officer

Exact text from the filing

On March 20, 2022, Hamza Suria, provided notice to the board of directors (the “Board”) of AnaptysBio, Inc. (the “Company”) of his resignation as President and Chief Executive Officer and as a Class II director of the Company, effective immediately.

View on SEC.gov

ANAPTYSBIO, INC filing history →

Source: SEC EDGAR

accession 0001370053-22-000017

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.